Eli Lilly & Co. (LLY) Financials
Key financial figures for Eli Lilly & Co. (Q3 2026).
Lilly Q3 2026 revenue rose 39% to $24.4 billion on Mounjaro and Zepbound, and full-year revenue guidance was raised to $91.0 to $92.0 billion. Revenue was $24,397 million, up 39% from $17,601 million a year earlier, on a 53% volume increase partly offset by a 15% decline in realized prices. The release says about $900 million of the quarter's revenue was benefits, primarily $410 million of Jardiance milestones and favorable rebate and discount estimate adjustments. Mounjaro revenue was $10,723 million (up 65%) and Zepbound was $5,352 million (up 49%); together $16,075 million, about two thirds of total revenue. Foundayo, the oral GLP-1 launched in Q2, contributed $184 million. On the outlook: 2026 full-year revenue raised to $91.0 to $92.0 billion (prior $85 to $87 billion); performance margin 52.0% to 52.5% (prior 49.0% to 50.5%); tax rate 19% to 20% (prior 18% to 19%); non-GAAP EPS $35.00 to $36.00 (prior $35.50 to $36.50), which includes $4.57 of Q3 acquired IPR&D charges and excludes IPR&D incurred after September 30, 2026. Figures are for Q3 2026, as Eli Lilly and Company reported them.
- Revenue
- $24.4B
- Net Income
- $6.5B
- EPS
- $7.23
- Total Assets
- $148.1B
- Operating Cash Flow
- $11.4B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $24.4B | $6.5B | $7.22 | $8.2B | |
| Q2 FY2026 | $23.0B | $7.1B | $7.94 | $7.8B | |
| Q1 FY2026 | $19.8B | $7.4B | $8.26 | $3.0B | |
| Q4 FY2025 | $19.3B | $6.6B | $7.39 | $678M | |
| Q3 FY2025 | $17.6B | $5.6B | $6.21 | $8.6B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $65.2B | $20.6B | $22.95 | $9.0B | |
| FY2024 | $45.0B | $10.6B | $11.71 | $3.8B | |
| FY2023 | $34.1B | $5.2B | $5.80 | -$3.2B |
Frequently asked questions
What was Eli Lilly and Company's revenue last quarter?
Eli Lilly and Company reported revenue of $24.40 billion for Q3 FY2026, up 38.6% from the same period a year earlier.
Is Eli Lilly and Company profitable?
Yes. Eli Lilly and Company reported net income of $6.45 billion for Q3 FY2026, a net margin of 26.44% on revenue.
How much free cash flow did Eli Lilly and Company generate?
Eli Lilly and Company generated free cash flow of $8.22 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Eli Lilly & Co. on SentiSense, with up to forty quarters and twenty fiscal years of history.